Join Growin Stock Community!

東生華8432.TW Overview

TW StockBiotech. & Medical
(No presentation for 8432)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

東生華（8432）Overall Performance

東生華（8432）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

東生華（8432） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

東生華（8432）Key Information

東生華（8432）Profile

TSH Biopharm Corporation Limited develops and markets pharmaceutical products in Taiwan and Asia. It offers products for cardiovascular, central nervous, gastrointestinal, and others. The company was founded in 1999 and is headquartered in Taipei city, Taiwan. TSH Biopharm Corporation Limited is a subsidiary of TTY Biopharm Company Limited.

東生華（8432）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

No related data records

default symbol

8432

東生華

54.40D

-1.10%

(-0.01)

  • When is 8432's latest earnings report released?

    The most recent financial report for 東生華 (8432) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 8432's short-term business performance and financial health. For the latest updates on 8432's earnings releases, visit this page regularly.

  • What is the operating profit of 8432?

    According to the latest financial report, 東生華 (8432) reported an Operating Profit of 84.25M with an Operating Margin of 19.94% this period, representing a growth of 14.19% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 8432's revenue growth?

    In the latest financial report, 東生華 (8432) announced revenue of 422.58M, with a Year-Over-Year growth rate of 8.76%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 8432 have?

    At the end of the period, 東生華 (8432) held Total Cash and Cash Equivalents of 588.64M, accounting for 0.29 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 8432 go with three margins increasing?

    In the latest report, 東生華 (8432) achieved the “three margins increasing” benchmark, with a gross margin of 47.84%%, operating margin of 19.94%%, and net margin of 19.15%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 8432's profit trajectory and future growth potential.

  • Is 8432's EPS continuing to grow?

    According to the past four quarterly reports, 東生華 (8432)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 1.53. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 8432?

    東生華 (8432)'s Free Cash Flow (FCF) for the period is -38.28M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 15.01% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.